Purpose To report outcomes of a population of anal cancer patients treated with modern intensity-modulated radiotherapy and daily image-guided radiotherapy techniques. Methods We analyzed data of 155 patients consecutively treated with intensity-modulated radiotherapy +/− chemotherapy in three radiotherapy departments. One hundred twenty-two patients presented a stage II-IIIA disease. Chemotherapy was administered in 138 patients, mainly using mitomycin C and 5-fluorouracil (n = 81). All patients received 36 Gy (1.8 Gy/ fraction) on the pelvic and inguinal nodes, on the rectum, on the mesorectum and on the anal canal, and a sequential boost up to a total dose of 59.4 Gy (1.8 Gy/fraction) on the anal canal and on the nodal gross tumor volumes. Results Median follow-up was 38 months (interquartile range 12-51). Toxicity data were available for 143 patients: 22% of them presented a G3+ acute toxicity, mainly as moist desquamation (n = 25 patients) or diarrhea (n = 10). Three patients presented a late grade 3 gastrointestinal toxicity (anal incontinence). No grade 4 acute or late toxicity was recorded. Patients treated with fixed-gantry IMRT delivered with a sliding window technique presented a significantly higher risk of acute grade 3 (or more) toxicity compared to those treated with VMAT or helical tomotherapy (38.5 vs 15.3%, p = 0.049). Actuarial 4-year local control rate was 82% (95% CI 76-91%). Conclusions Modern intensity-modulated radiotherapy with daily image-guided radiotherapy is effective and safe in treating anal cancer patients and should be considered the standard of care in this clinical setting.
Introduction
Anal cancer is rare, but its incidence is increasing (http:// www.nccn.org/profe ssion als/physi cian_gls/f_guide lines .asp#anal. Accessed 08 May 2016). Since the publication of randomized controlled trials (RCT) published in the '90s, the standard treatment of squamous-cell anal carcinoma is external beam radiotherapy (EBRT) with Berardino De Bari and Laëtitia Lestrade contributed as first authors to this study.
Mahmut Ozsahin and Thomas Zilli contributed as senior authors to this study. concomitant chemotherapy (CT) (Bartelink et al. 1997; UKCCCR Anal Cancer Trial Working Party 1996; Flam et al. 1996) .
The overall rate of non-hematological grade 3-4 acute and late toxicity reported in the RCTs and in large retrospectives series were 54-74, and 11-36%, respectively (Bartelink et al. 1997; UKCCCR Anal Cancer Trial Working Party 1996; Flam et al. 1996; Lestrade et al. 2014; Glynne-Jones et al. 2014) . Noteworthy, in all these RCTs, radiotherapy was delivered with 2D-or, at the best, 3D-EBRT techniques.
Intensity-modulated radiation therapy (IMRT) preferentially targets treatment volumes, while minimizing doses to adjacent normal critical structures. Compared to 3D-EBRT, the potential of IMRT in improving the therapeutic ratio of the treatments has been already shown in several diseases (Gomez-Millan et al. 2013; De Bari et al. 2014; Bauman et al. 2012 ). More evolved forms of IMRT, such as volumetric modulated arc radiotherapy (VMAT) or helical tomotherapy (HT), have been recently introduced also in the treatment of anal cancer. These techniques of irradiation showed interesting dosimetric improvements in some studies compared to "standard" IMRT (Clivio et al. 2009; Brooks et al. 2013; Ugurluer et al. 2015) . Moreover, imageguided radiation therapy (IGRT) is being largely adopted in the daily clinical practice, as it allows the online and offline daily verification and correction of the setup of the patients and a reduction of treatment volumes, with a consequent reduction of toxicity rates (Conde-Moreno et al. 2012; Hajj and Goodman 2015) . IMRT and IGRT have been recently adopted also in the treatment of anal canal cancer patients, and results are promising in terms of local control and toxicity (De Bari et al. 2016; Han et al. 2014; Lestrade et al. 2017; Kachnic et al. 2013; Vieillot et al. 2012; Call et al. 2016) , with a particular interest in some particular classes of patients, presenting an intrinsic increased risk of higher toxicity (Lestrade et al. 2013; Hauerstock et al. 2010; White et al. 2017) . Unfortunately, the sample size of studies reporting the results of IMRT in anal cancer treatment was often limited, with also short follow-up time (often < 24 months).
In the radiotherapy departments involved in this study, IMRT and IGRT are standards of care for anal cancer patients, as it is considered that using daily IGRT, smaller "CTV-to-PTV" margins could be applied, thus potentially reducing the toxicity of the treatments. We retrospectively analyzed efficacy and toxicity of this more conservative strategy adopted in 3 Swiss radiation oncology departments (Centre Hospitalier Universitaire Vaudois-CHUV, Hôpitaux Universitaires de Genève-HUG, and Clinical Luganese-CL). Primary endpoints were ≥ grade 3 toxicity rate (CTC-AE v.4.0) and local control (LC). Secondary endpoints were actuarial overall (OS), disease-free (DFS), cancer-specific (CSS), metastases-free (MFS) and colostomy-free survival (CFS) rates.
Methods and materials

Population and treatment
Patients with a histologically proven anal cancer treated with curative intent with pelvic EBRT +/− CT, and a sequential boost delivered on the macroscopic nodal and tumor site [using the radiotherapy schedule of the EORTC 22953 study (Bosset et al. 2003) ] were included in this retrospective analysis. Tumors were retrospectively re-staged according to the 2002 International Union against Cancer Classification staging system (UICC 2002) (Sobin and Gospodarowicz 2009) . Before the treatment, all of them received physical examination with digital rectal exploration (DRE) and ano-rectal echo-endoscopy. For the nodal and systemic staging, all of them underwent total body injected CT scan. Patients were treated between 09/2007 and 03/2015: as consequence, 18 FDG PET-CT and MRI were not performed in all the patients and were initially limited to those presenting a clinical suspicion of locally advanced disease.
Generally, patients were followed in the radiation oncology departments for at least 2 years after the end of the treatment. They underwent a visit with DRE and echoendoscopy every 3 months in the first and the second year, every 6 months until the fifth year, and yearly thereafter. CT scan was performed every 6 months during the first 5 years, then yearly. Some of the patients, living far from our hospitals, continued their follow-up with their general practitioners with the same follow-up methods usually adopted in our departments and who readdressed the patients to our attention in case of suspicion of relapse.
Primary endpoints of this analysis were acute and late toxicity rates and LC.
Statistical analysis
Initially, we performed a descriptive analysis of the whole population, including acute and late toxicity, retrospectively scored using the Common Toxicity Criteria Adverse Event score (CTCAE v.4 .0) (National Cancer Institute 2009). Toxicity recorded up to 6 months from the end of the treatment was considered as acute toxicity, while all others were considered as late toxicities. In doubtful cases, the toxicity was upgraded.
Considered events were death (all causes) for OS, cancer-related death for CSS, death (all causes) or relapse for disease-free survival (DFS), or local relapse at the anal level for LC, or any systemic relapse for MFS, or colostomy (any cause) for the CFS. For all the considered endpoints, the date of biopsy was used as initial reference 1 3 time. The dates of deaths were confirmed using death certificates. In patients with unknown cause of death, and still presenting a clinical or a pathologic evidence of active and/or recurrent disease at last follow-up, deaths were attributed to anal cancer. Fisher's exact test for values of less than 5 was used to compare proportion, while the Kaplan-Meier method was adopted to estimate the survival curves (Kaplan and Meier 1958) . All these survival rates are reported as actuarial rates. Table 1 summarizes variables studied in univariate analyses for the primary and secondary endpoints. In univariate analyses, differences between groups were assessed using the log-rank test (Peto and Peto 1972) . Prognostic factors with a p value of less than 0.2 in univariate analyses were included in the multivariate model (calculated with the Cox regression test (Cox 1975) ), to define the independent contribution of each prognostic factor. Confidence intervals (CI) were calculated from standard errors. In all these analyses, a p value < 0.05 was considered as statistically significant.
Radiotherapy
After a median delay from biopsy of 46 days (range 10-194 days), all patients received IMRT to the anal canal and pelvic nodal areas. Anal canal, mesorectal, pelvic, and inguinal nodes received a total dose of 36 Gy (1.8 Gy/ fr) using fixed-gantry sliding-window IMRT (n = 39) or VMAT (n = 15), or HT (n = 97). The upper limit of the contouring of the pelvic volume was usually identified at the L5-S1 level. All patients were treated on the inguinal nodes with a prophylactic and/or curative goal.
A planned 2-week gap was adopted in 123 patients (no gap in 28 patients). Median duration of the gap was 11 days (range 5-26). After the first course of pelvic irradiation, a complementary dose of 23.4 Gy was delivered with either IMRT (n = 16, until 2011), VMAT (n = 17), HT (n = 61) or 3D-conformal EBRT (CRT, n = 61). Target volumes for the sequential boost consisted of anal canal and the positive nodes plus 1-1.5 cm of margin. The respective planning target volumes (PTVs) were defined as the clinical target volumes (CTVs) plus a 5-mm margin. Median overall treatment time for EBRT with or without CT was 57 days (interquartile range 52-59). The dosimetric constraints were similar in the three centers and have been previously described (De Bari et al. 2016) . In two out the three participating Centers (CHUV and CL), the IGRT was performed with daily MV-CBCT performed with HT. In the HUG, the setup of the patient was verified with a daily planar 2D imaging with kilovoltage (kV) energies and a weekly KV-Cone-Beam CT (CBCT). This protocol was adapted, with more than one CBCT/week (up to daily CBCT, if necessary) in case of patients presenting more difficulties in the daily setup. Corrections to the setup of the patients were adopted before the delivery of the treatment depending on the results of the IGRT protocol, if the deviation that was found was higher than the CTV-to-PTV margin.
Chemotherapy
Concomitant CT was administered in 138 patients, most of whom (n = 131) received mitomycin C (10-15 mg/m 2 given on the day 1 and on the day of the beginning of the sequential boost), usually combined either with 5-fluorouracil (5-FU, 1000 mg/m 2 /day on the first five and last five days of RT, n = 82) or Capecitabine (825 mg/m 2 /day, every 12 h, on the from Monday to Friday during the whole RT course, n = 49). The decision of delivering or not a concomitant chemotherapy was taken by the medical oncologist, who also decided the type of chemotherapy to be given depending on the clinical situation of the patient. 
Results
Patient and tumor characteristics
One-hundred fifty-one patients were treated between 09/2007 and 03/2015. Twenty-seven, 61, 32, 29, and 2 patients presented stage I, II, IIIA, IIIB, and IV disease, respectively. Median age was 62 years (range 37-90). Twenty-six patients were ≥ 75 years old (17%). Table 2 summarizes the main features of the patients included in this analysis.
Clinical results
Median follow-up period for the whole population was 38 months (interquartile range 12-51).
Toxicity
Complete data about acute toxicity were available for 143/151 patients. Overall, grade 3 acute toxicity was observed in 32 patients (22%), mainly as erythema with moist desquamation (n = 25) or diarrhea (n = 10). At the time of analysis, 137 patients presented more than 6 months of follow-up, and were considered evaluable for late toxicity. We also analyzed whether the risk of toxicity could be increased depending on some technical variables. No statistical differences in terms of severe toxicity were recorded according to the boost technique (any IMRT vs 3D-EBRT). The IGRT protocol has no impact on the risk of acute toxicity.
Looking at the technique of irradiation of the pelvis, the patients treated with sliding-window IMRT presented a significantly higher risk of acute grade 3 (or more) toxicity compared to those treated with VMAT or HT (38.5 vs 15.3%, p = 0.049). The same difference was not seen when HT was compared to the other two techniques of IMRT (HT = 14%; other = 28.6%, p = 0.1).
To take into account some of the characteristics of the patients within the two groups that could potentially influence these results (ex. Stage I-II vs III-IV, concomitant chemotherapy vs no chemotherapy, age), some Ficher's exact tests were performed. p values of all these analyses were negative, and the two groups (IMRT vs HT + VMAT) could be considered homogeneous.
Finally, age (≤ 75 vs. >75 years or ≤ 62 vs. >62 years) had no impact on the risk of developing severe acute or late toxicity.
Local control
Median LC time was not reached, with an actuarial 4-year LC rate of 82% (95% CI 76-91%). Figure 1 shows the LC rates of the whole population. Two patients had stage IV disease at diagnosis. Both these patients have been treated with a curative goal and were alive and disease-free the moment of this analysis, 43 and 66 months after the end of the treatment. Details about these patients have been previously reported (De Bari et al. 2016) .
According to the technique used to deliver the boost (3D vs any IMRT), overall 4-year LC was not statistically Noteworthy, only four patients presented a concomitant nodal relapse, and only two of them presented a nodal only relapse. None of them presented an inguinal relapse.
A total of 13 patients received a colostomy, 11 for a local relapse and 2 before the treatment (sub-occlusive disease). None of the patients received a colostomy because of treatment related toxicity.
Other clinical outcomes
Overall survival The 4-years OS was 82% (95% CI 75-90%). Figure 2 shows the OS rates of the whole population. Women presented higher 4-year OS rates compared to men (88 vs 60%, p = 0.01). Elderly patients (> 75 years old) showed a lower 4-year OS (53 vs 87%, p < 0.001). Patients presenting T1 or T2 tumors presented a higher 4-year OS compared to T3 and T4 patients (89 vs 67%, p = 0.007), and this trend is confirmed when T4 patients are compared to T1-3 patients (60 vs 87%, p = 0.016). Stage I and II patients presented higher 4-year OS rates compared to stage III-IV patients (90 vs 70%, p = 0.03). Table 3 summarizes the results of multivariate analysis.
Cancer-specific survival The 4-year CSS was 90% (95% CI 89-91%).
Women presented higher 4-year CSS rates compared to men (93 vs 73%, p = 0.02). Elderly patients (> 75 years old) showed a lower 4-year CSS (70 vs 94%, p = 0.02). Also patients older than the median age of the whole population (62 years) showed lower 4-year CSS rates (81 vs 97%, p = 0.02). Globally, patients presenting early cancers presented higher CSS (p < 0.001). Patients presenting T1 or T2 tumors presented a higher 4-year CSS compared to T3 and T4 patients (95 vs 75%, p = 0.004), and this trend is confirmed when T4 patients are compared to T1-3 patients (74 vs 93%, p = 0.016). Stage I and II patients presented higher 4-year CSS rates compared to stage III-IV patients (95 vs 82%, p < 0.001). Table 3 summarizes the results of multivariate analysis.
Disease-free survival
The 4-year DFS was 82% (95% CI 74-89%). Women presented higher 4-year DFS rates compared to men (87 vs 59%, p = 0.002). Patients presenting T1-3 tumors presented a higher 4-year DFS compared to T4 patients (85 vs 70%, p = 0.03). Stage I and II patients presented higher This impact of the planned gap was not found at the multivariate analysis: indeed, finally, only a stage III or IV unfavorably influenced the DFS (RR = 1.1 ± 0.46, p = 0.03) (see Table 3 ).
Metastases-free survival
The 4-year DFS was 93% (95% CI 89-97%).
Patients with fixed tumors presented a lower 4-year MFS (87 vs 96%, p = 0.04). Globally, patients presenting early T stages and early N stages presented higher MFS (p < 0.001). Considering that only nine patients (6%) presented a systemic progression, we did not consider correct to perform any further univariate analysis.
Discussion
In our population of 151 anal cancer patients, treated with IMRT, usually delivered with modern techniques of IMRT (HT or VMAT) and daily IGRT (74%), we showed an actuarial 4-year LC rate of 82% and encouraging rates of acute (22%) and late toxicity (2%). A roughly comparison with the results of the RCTs, our study shows a better toxicity profile, also considering that in 28/151 patients (18%) we did not plan a gap between the pelvic irradiation and the boost, and that 50% of the remaining patients were treated with a gap of less than 2 weeks. The LC rates were not statistically affected by the technique of treatment and could be considered comparable to those obtained in the RCTs http://www. nccn.org/profe ssion als/physi cian_gls/f_guide lines .asp#anal. Accessed 08 May 2016; Bartelink et al. 1997; UKCCCR Anal Cancer Trial Working Party 1996; Flam et al. 1996; Glynne-Jones et al. 2014) .
Some important drawbacks of this series should be underlined as they could potentially influence our results. The main issues in this area are around the lack of MR data for staging, assessment of response and definition of recurrence, and the use of a "gap" in treatment which was applied for most of patients. These limitations are clearly related to the considered treatment period. The lack of MRI staging is particularly important for defining nodal disease and incorporating this into IMRT planning. It is of concern that the lack of MR staging, although it might not have much influence on T staging, would be highly likely to affect the N staging and the subsequent target definition for planning. Moreover, data on local control are difficult to define on CT, particularly nodal relapse. This accentuates the impact of the lack of MRI assessment in our series. Nowadays, MRI is realized in the pre-treatment evaluation of all our patients and is adopted in restaging of all the patients presenting a suspicion of local relapse. Looking at the adoption of the gap, patients treated more recently in this series, and more in general all our patients treated after 2012, received a sequential boost without gap because of a change in our policies of treatment. Longer follow-up and larger populations are needed before to evaluate the impact of these new approaches in staging and treatment on the clinical outcomes of our patients. Moreover, the retrospective nature of the study is a clear bias in the evaluation of our results in terms of outcomes and toxicity. For example, the number of fixed tumors in our series was quite high (63%) and yet our results remain very good. This may suggest overstaging in some cases as they were retrospectively staged.
In RCTs, pelvic irradiation was delivered using two-or three-dimensional (D) approaches. Also considering that contouring guidelines for anal cancer are available only since 2009 (Myerson et al. 2009 ), it could be easily argued that these experiences could not be considered anymore as references in the modern era of radiotherapy, as a large amount of normal tissues (bladder, bowel, perineal region, inguinal skin) where included in the treatment volumes of RTCs.
As consequence, high rates of grade 3-4 gastrointestinal (GI) side effects were reported in these studies, up to 35% (mainly diarrhea) (Ajani et al. 2008 ). These high rates of severe toxicity are consistent with those of more recent retrospective large series using 2D-or 3D-EBRT techniques (De Bari et al. 2014a, b) .
Intensity-modulated radiation therapy already showed a reduction of the doses delivered to small bowel, femoral head, perineum and genitalia compared to 3D-EBRT in several dosimetric studies (Ugurluer et al. 2015; Chen et al. 2005; Jones Joseph et al. 2010; Milano et al. 2005) .
The RTOG 0529 trial (http://www.rtog.org/Clini calTr ials/ Proto colTa ble/Study Detai ls.aspx?study =0529; accessed 08 Feb 2015) was designed to show that IMRT could improve of at least 15% the rate of grade 2 or more acute GI and genitourinary (GU) toxicity, taking as reference the results of the RTOG 98-11 (Gunderson et al. 2012) . The trial was negative, but IMRT arm showed a significant reduction in acute toxicity for ≥ grade 3 cutaneous (23 vs. 49%), GI (21 vs. 36%) toxicity (Kachnic et al. 2013) . Similar data are reported in a multi-institutional retrospective study published by Salama et al., showing a rate of 15.1% of grade 3 acute GI toxicity (Salama et al. 2007) , lower than the rate reported in the RTOG 98-11 trial (Gunderson et al. 2012) . De Bari et al. showed an overall rate of 22% of acute toxicity (mainly cutaneous), in a large monocentric series of patients treated with tomotherapy (De Bari et al. 2016) . Franco et al. (2016) showed comparable rates of acute toxicity in a retrospective analysis of 39 patients treated with VMAT and simultaneous integrated boost (SIB). The same team published later data about the efficacy of this schedule in the same population: their data showed encouraging LC, DFS and OS rates (Arcadipane et al. 2017) . These data have been confirmed by Mitra et al. (2017) in a larger, long-term experience on 99 patients treated with VMAT-SIB delivered with the schedule of the RTOG 0529 trial: at a median follow-up of 49 months (range 2-114 months), the 4-year overall survival was 85.8%, and 4-year event-free survival was 75.5%. The overall rate of non-hematologic grade 3+ acute and grade 2+ late toxicities was 20 and 15%, respectively.
All these dosimetric and clinical data seem to support the idea that future prospective trials should include IMRT as standard EBRT modality, as stated also in the editorial by Herman and Thomas (2013) . Our results on a large population of patients treated with IMRT compare favorably with the other IMRT series, with an overall rate of grade 3 acute toxicity of 21.2%, mainly as erythema (n = 25/33). Moreover, we also showed that modern techniques of IMRT, as VMAT or HT, could potentially further improve the results in terms of severe toxicity compared to standard IMRT. These results confirmed the dosimetric findings by Viellot et al. (2010) , showing the same coverage, but a better organ at risk sparing when volumetric IMRT with two arcs (delivered with RapidArc in their study) was compared to fixed beam IMRT. Moreover, looking at the results of the RTOG 0529 trial, and the data published using the same protocol in other institutional series, the SIB seems to be of major interest in the treatment of anal cancer patients, also considering its potential in shortening the OTT.
In our experience, two important aspects are noteworthy: the adoption of IGRT and the delivered doses. Indeed, all patients underwent a daily verification of their setup with different IGRT protocols. This allowed adding only 5 mm to the CTV to obtain the PTV, thus obtaining smaller volumes. A direct comparison with the volumes treated in the previous reports is clearly not possible, but it could be easily argued that our approach allows their reduction, thus lowering the risk of toxicity. Moreover, doses adopted in participating departments are the lower than the 45-50.4 Gy delivered in the RCTs (Bartelink et al. 1997 ; UKCCCR anal cancer trial working party 1996; Flam et al. 1996) . The efficacy of similar dose levels has been recently reported by Lépinoy et al. (2015) in a series of 142 patients treated with 3D techniques: the authors reported a 5-years LC rate of 81%. An argument against the use of lower doses of prophylactic radiotherapy is the potential risk of higher nodal relapse rates, in particular at the inguinal level. In the study by Lepinoy et al. the 5-year inguinal control rate was 98.5%, quite comparable to our 4-and 5-year rates of 100%. These results in terms of efficacy and in terms of toxicity support the adoption of lower doses of radiotherapy, and the schedules including the prophylactic inguinal irradiation.
The introduction of very conformal radiotherapy techniques (such as IMRT) and/or the use of smaller "CTV to PTV" margins could potentially lead to a higher risk of target missing and, therefore, reduce the local control, as suggested in a recent paper by Bagshaw et al. dealing with the rate of vaginal relapses in patients with anal cancer treated with IMRT (Bagshaw et al. 2016 ). In our series of 151 patients treated using VMAT or HT combined with daily IGRT and concomitant CT, after a median follow-up of 38 months, we observed a 4-year LC of 82%, which is at least comparable to the LC rates reported in major randomized studies (Bartelink et al. 1997 ; UKCCCR anal cancer trial working party 1996; Flam et al. 1996) . We conclude that our dose levels, with 36 Gy delivered on the prophylactic larger volume and a boost up to 59.4 Gy on the macroscopic disease, delivered with IMRT and IGRT are safe and effective, and should be considered a standard of care for the treatment of anal cancer patients.
Overall treatment time is of paramount importance in anal cancer, as it could unfavorably affect the outcomes of the patients: the 2-year colostomy rate of the RTOG 92-08 trial, including a planned 2-week break during treatment, was of 30% (Flam et al. 1996) , higher than the 5-year colostomy rate of the RTOG 98-11 trial (10%), without planned gaps (Gunderson et al. 2012 ). In our study, median overall treatment time for the entire treatment was 57 days, higher than the RTOG 05-29 study (43 days, range 32-59), and then the RTOG 98-11 (49 days; range 4-100) (Flam et al. 1996; Gunderson et al. 2012) . Nevertheless, our 4-year LC rates (81%) are at least comparable to those recorded in the major randomized trials, ranging between 64 and 68% (Bartelink et al. 1997 ; UKCCCR anal cancer trial working party 1996; Flam et al. 1996) . In our analysis, an overall treatment time of more than 57, 60, or 63 days did not decrease the 4-year LC. The EORTC pooled analysis of radiation oncology trials in anal cancer (PARADAC), presented during ESTRO 2013, confirmed that for patients treated after 1994 with a combination of radiation and two chemotherapeutic drugs, a longer duration of radiation therapy was detrimental to the outcome of patients (Matzinger et al. 2013) . Noteworthy, in this EORTC analysis, patients receiving 59.01-59.4 Gy (as in our population) did not show an impact of the OTT, thus confirming our results.
Nevertheless, looking at the available literature, we still consider that a shorter OTT should be suggested in the treatment of anal cancer patients, and that a gap should be considered only in patients presenting severe toxicities at the end of the pelvic irradiation.
Conclusions
We showed that modern IGRT-IMRT (delivered using VMAT or HT) is safe and effective in the treatment of patients with squamous-cell carcinoma of the anal canal.
3
The non-hematological toxicity rate is drastically reduced without increasing the local or loco-regional failures rates. Therefore, IGRT-IMRT should be considered as the standard of care in the treatment of anal canal cancer patients.
